(Q44923726)

7 December 2017

title

Control of blood glucose by novel GLP-1 delivery using biodegradable triblock copolymer of PLGA-PEG-PLGA in type 2 diabetic rats (English)

1 reference

7 December 2017

0 references

Suna Choi

1

1 reference

7 December 2017

Miroslav Baudys

series ordinal

2

1 reference

7 December 2017

Sung Wan Kim

series ordinal

3

1 reference

7 December 2017

publication date

1 May 2004

1 reference

7 December 2017

published in

Pharmaceutical Research

1 reference

7 December 2017

volume

21

1 reference

7 December 2017

issue

5

1 reference

7 December 2017

page(s)

827-831

1 reference

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

7 December 2017

cites work

1 reference

12 December 2020

The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus

1 reference

12 December 2020

Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.

1 reference

12 December 2020

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

1 reference

12 December 2020

Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects

1 reference

12 December 2020

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

1 reference

12 December 2020

Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells

1 reference

12 December 2020

Biodegradable block copolymers as injectable drug-delivery systems

1 reference

12 December 2020

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

12 December 2020

Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.

1 reference

12 December 2020

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

1 reference

12 December 2020

Controlled release of insulin from injectable biodegradable triblock copolymer

1 reference

12 December 2020

The effect of zinc-crystallized glucagon-like peptide-1 on insulin secretion of macroencapsulated pancreatic islets

1 reference

12 December 2020

Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.

1 reference

12 December 2020

Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

1 reference

12 December 2020

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

12 December 2020

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

1 reference

12 December 2020

Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment

1 reference

12 December 2020

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

12 December 2020

Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

1 reference

12 December 2020

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

1 reference

12 December 2020

10.1023/B:PHAM.0000026435.27086.94

Identifiers

DOI

1 reference

7 December 2017

1 reference